Mayo Clinic study shows plasma therapy may reduce COVID-19 mortality

Mayo Clinic study shows plasma therapy may reduce COVID-19 mortality Photo: Mayo Clinic News Network.

Created: August 14, 2020 03:14 PM

(ABC 6 News) - Mayo Clinic and collaborators have published details on a three-month study that uses plasma to treat patients in the hospital with COVID-19. 

Researchers report that in the initial experience, that the timing of plasma transfusions in 35,322 patients was associated with lower mortality. 


The study uses convalescent plasma. According to the FDA, it is the liquid part of blood that is collected from patients who have recovered from COVID-19 and have developed antibodies. 

Mayo Clinic reports that 52.3% of these patients were in the ICU at the time of receiving that plasma. And of those, 27.5% were on a ventilator. 

They also report that in over 3,000 patients, they found lower mortality associated with plasma transfusions that contained higher levels of antibodies against the virus that causes COVID-19. 

Specifically, they found that the seven-day mortality rate was reduced when patients were treated within three days of diagnosis. This compares to those that were treated four or more days. Also, the use of plasma with higher antibody levels was associated with reduced seven-day and 30-day mortality.  

This study includes adult participants around the U.S. between April 4 and July 4 who were in the hospital with severe or life-threatening acute COVID-19 respiratory syndrome. The data are extracted from the Mayo-led national Expanded Access Program (EAP) for convalescent plasma for the treatment of hospitalized patients with COVID-19.

Read the published preprint here.

Copyright 2020 - KAAL-TV, LLC A Hubbard Broadcasting Company

Comment on Facebook